Vaxart, Inc. Files 8-K Report
Ticker: VXRT · Form: 8-K · Filed: Jul 8, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-history
TL;DR
Vaxart filed an 8-K, standard procedure, no new info in this snippet.
AI Summary
On July 8, 2025, Vaxart, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific new material events or financial details disclosed in the provided excerpt. The company, formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS, is based in South San Francisco, California.
Why It Matters
This 8-K filing indicates Vaxart, Inc. is fulfilling its reporting obligations with the SEC, though the excerpt does not reveal new material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report without disclosure of new material events or financial changes, thus posing low immediate risk.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Aviragen Therapeutics, Inc. (company) — Former Company Name
- Biota Pharmaceuticals, Inc. (company) — Former Company Name
- NABI BIOPHARMACEUTICALS (company) — Former Company Name
- July 8, 2025 (date) — Date of Report
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Vaxart, Inc. on July 8, 2025?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating routine SEC reporting.
What were Vaxart, Inc.'s previous names?
Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.
Where are Vaxart, Inc.'s principal executive offices located?
Vaxart, Inc.'s principal executive offices are located at 170 Harbor Way, Suite 300, South San Francisco, California.
Does this excerpt of the 8-K filing reveal any new financial results or material business developments?
No, the provided excerpt of the 8-K filing does not disclose specific new financial results or material business developments.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 8, 2025 regarding Vaxart, Inc. (VXRT).